Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Innovent Biologics, Inc. (IVBXF)
Suzhou, CN
Innovent Biologics, Inc. is a biopharmaceutical firm headquartered in Suzhou, People's Republic of China, established in 2011. It specializes in the discovery, advancement, and production of antibody-based drug candidates, with a strategic focus on therapeutic areas including cancer treatment (oncology), eye conditions (ophthalmology), immune system disorders (immunology), and metabolic ailments. Innovent's flagship therapeutic offering is Tyvyt (sintilimab), an anti-PD-1 monoclonal antibody utilized in managing various cancers, including Hodgkin's lymphoma and esophageal carcinoma. Additionally, its portfolio includes several other approved treatments: Byvasda, for diverse malignant tumors; Halpryza, addressing non-Hodgkin's lymphoma, chronic lymphocytic leukemia, and Wegener's granulomatosis; Pemazyre, indicated for adults with advanced or metastatic cholangiocarcinoma; Olverembatinib, developed for adult patients requiring tyrosine kinase inhibitor treatment; and Cyramza, which targets four distinct cancer types. Beyond its commercialized products, Innovent maintains a robust pipeline of investigational therapies. These include IBI-301, a rituximab biosimilar for non-Hodgkin's lymphoma; IBI-302, a bispecific antibody fusion protein aimed at ocular fundus disease; IBI-306, a human monoclonal antibody designed to combat hypercholesterolemia; and IBI-310, a recombinant human anti-CTLA-4 monoclonal antibody being explored for liver cancer and renal cell carcinoma. The company is also advancing IBI-188, an anti-CD47 monoclonal antibody for advanced hematological and solid tumors; IBI-326, a fully human BCMA-CAR T-cell therapy targeting relapsed or refractory multiple myeloma in adults; IBI-376, for recurrent or refractory follicular lymphoma; and IBI-112, designated for psoriasis. Moreover, Innovent provides pharmaceutical product distribution services, alongside offering expert consultation and engaging in research and development activities. Its operational strategy is further bolstered by strategic alliances with partners such as NeoCura Bio-Medical Technology Co. Ltd., Roche Group, Ascentage Pharma Group International, Eli Lilly and Company, and Bolt Biotherapeutics, Inc.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +12.89% | +4.21% | -4.22% | -4.65% | -10.95% | +10.51% | +37.96% | +125.42% | -10.21% | +241.59% | +241.59% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
-
Revenue growth Biotechnology: +1.6%+34.9% ★ Q4'25: +98.9% (vs Q4'23)
-
EPS growth Biotechnology: +29.7%+915.6% ★ Q4'25: +95.6% (vs Q4'23)
-
FCF margin FCF growth · Biotechnology: +16.2%+77.2% Q4'25: +135.3% (vs Q4'23)
-
EBIT margin Biotechnology: +0.0%+15.5% ★ Q4'25: +10.3% (vs Q4'23)
-
ROIC Biotechnology: -16.1%+48.4% ★ Q4'25: +43.6% (vs Q4'23)
-
Share dilution Biotechnology: -3.4%+7.0% Q4'25: -47.6% (vs Q4'23)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×1.43× ★ Q4'25: 0.98× (vs Q4'23)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 30 Rev. Ana. 1 EPS Ana. |
Dec 2027 29 Rev. Ana. 1 EPS Ana. |
Dec 2028 22 Rev. Ana. 1 EPS Ana. |
Dec 2029 18 Rev. Ana. 1 EPS Ana. |
Dec 2030 14 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
9.48M
est: 10.09M (-6.1%)
|
1.05B
est: 861.38M (+21.6%)
|
3.84B
est: 3.22B (+19.4%)
|
4.27B
est: 4.08B (+4.6%)
|
4.56B
est: 4.61B (-1.2%)
|
6.21B
est: 5.98B (+3.8%)
|
9.42B
est: 8.27B (+14.0%)
|
12.70B
est: 12.99B (-2.2%)
|
19.00B
15.51B – 28.28B
+46.3% YoY
|
22.77B
18.51B – 27.07B
+19.8% YoY
|
26.91B
21.92B – 35.65B
+18.2% YoY
|
34.03B
27.72B – 45.09B
+26.5% YoY
|
38.81B
31.61B – 51.42B
+14.0% YoY
|
| EBITDA |
-5.74B
est: -2.59M (-221,875.1%)
|
-1.57B
est: -220.66M (-613.4%)
|
-704.74M
est: -824.46M (+14.5%)
|
-2.37B
est: -1.05B (-127.2%)
|
-1.75B
est: -1.18B (-48.0%)
|
-660.68M
est: -1.53B (+56.9%)
|
-480.28M
est: -1.56B (+69.2%)
|
1.97B
est: -2.45B (+180.4%)
|
-3.58B
-5.33B – -2.92B
-46.3% YoY
|
-4.29B
-5.10B – -3.49B
-19.8% YoY
|
-5.07B
-6.72B – -4.13B
-18.2% YoY
|
-6.42B
-8.50B – -5.23B
-26.5% YoY
|
-7.32B
-9.69B – -5.96B
-14.0% YoY
|
| EBIT |
-5.80B
est: -3.05M (-189,977.3%)
|
-1.66B
est: -260.56M (-537.3%)
|
-790.36M
est: -973.56M (+18.8%)
|
-2.58B
est: -1.23B (-109.0%)
|
-2.07B
est: -1.40B (-48.3%)
|
-1.05B
est: -1.81B (+42.2%)
|
-755.87M
est: -1.90B (+60.3%)
|
1.97B
est: -2.99B (+165.8%)
|
-4.38B
-6.51B – -3.57B
-46.3% YoY
|
-5.25B
-6.24B – -4.26B
-19.8% YoY
|
-6.20B
-8.21B – -5.05B
-18.2% YoY
|
-7.84B
-10.39B – -6.39B
-26.5% YoY
|
-8.94B
-11.85B – -7.28B
-14.0% YoY
|
| Net Income |
-5.77B
est: -1.76B (-228.4%)
|
-1.72B
est: -1.88B (+8.5%)
|
-998.42M
est: -750.06M (-33.1%)
|
-2.73B
est: -2.09B (-30.3%)
|
-2.18B
est: -2.82B (+22.7%)
|
-1.03B
est: -1.25B (+17.5%)
|
-94.63M
est: -785.02M (+87.9%)
|
792.57M
est: 1.10B (-27.7%)
|
2.47B
1.87B – 3.51B
+125.0% YoY
|
3.96B
3.00B – 5.63B
+60.5% YoY
|
5.38B
4.08B – 7.66B
+36.0% YoY
|
7.80B
5.92B – 11.09B
+44.9% YoY
|
9.72B
7.37B – 13.82B
+24.6% YoY
|
| SGA |
413.51M
est: 6.50M (+6,259.6%)
|
1.45B
est: 554.85M (+160.9%)
|
1.78B
est: 2.07B (-14.2%)
|
3.61B
est: 2.63B (+37.4%)
|
3.43B
est: 2.97B (+15.3%)
|
3.85B
est: 3.85B (0.0%)
|
5.08B
est: 5.40B (-5.9%)
|
6.47B
est: 8.49B (-23.8%)
|
12.42B
10.14B – 18.48B
+46.3% YoY
|
14.88B
12.10B – 17.69B
+19.8% YoY
|
17.59B
14.32B – 23.30B
+18.2% YoY
|
22.24B
18.12B – 29.46B
+26.5% YoY
|
25.36B
20.66B – 33.60B
+14.0% YoY
|
| EPS |
-17.24
est: -1.08 (-1,496.7%)
|
-1.51
est: -1.15 (-30.8%)
|
-0.74
est: -0.46 (-60.6%)
|
-1.88
est: -1.29 (-46.1%)
|
-1.46
est: -1.73 (+15.7%)
|
-0.66
est: -0.77 (+13.8%)
|
-0.06
est: -0.45 (+87.1%)
|
0.47
est: 0.63 (-25.4%)
|
1.42
1.08 – 2.02
+125.0% YoY
|
2.27
1.73 – 3.23
+60.5% YoY
|
3.09
2.35 – 4.40
+36.0% YoY
|
4.48
3.40 – 6.37
+44.9% YoY
|
5.58
4.24 – 7.94
+24.6% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-28 | B- | 2/5 | 1/5 | 3/5 | 4/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-27 | B- | 2/5 | 1/5 | 3/5 | 4/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-22 | B- | 2/5 | 1/5 | 3/5 | 4/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-21 | B- | 2/5 | 1/5 | 3/5 | 4/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-18 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-15 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-13 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-11 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-07 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-06 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-05 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-30 | C+ | 2/5 | 1/5 | 2/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-28 | C+ | 2/5 | 1/5 | 2/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-22 | C+ | 2/5 | 1/5 | 2/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-21 | C+ | 2/5 | 1/5 | 2/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-17 | C+ | 2/5 | 1/5 | 2/5 | 4/5 | 2/5 | 1/5 | 2/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Invesco S&P Emerging Markets Momentum ETF EEMO | 0.39% | 100.4K | 0.29% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| De-Chao Yu | Co-Founder, Chairman & Chief Executive Officer | 6M | — |
| Hao Xi Ede | Executive Director & Fund Managing Partner | 1M | male |
| Qian Zhang | Chief Commercial Officer, General Manager & Executive Director | 622.3K | female |
| Hui Zhou | Chief R&D Officer for Oncology | — | — |
| Kaisong Zhou | Chief Operating Officer | — | — |
| Min Liu | Chief Commercial Officer | — | male |
| Raj Dhodda | Senior Vice President | — | — |
| Samuel Suhua Zhang | Global Chief Business Officer | — | — |
| Blake Salisbury | Senior Vice President | — | male |
| Zhengwei Song | Director of IR & Financial Strategy | — | female |
| Cong Ding | General Counsel | — | female |
| Fei You | Chief Financial Officer | — | female |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for IVBXF
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
